Stryker (NYSE:SYK) Upgraded at Barclays

Barclays upgraded shares of Stryker (NYSE:SYK) to a strong-buy rating in a research note published on Wednesday,Zacks reports.

A number of other research analysts also recently weighed in on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $317.00 target price on shares of Stryker in a research report on Wednesday, September 9th. Argus set a $370.00 price target on shares of Stryker in a research report on Thursday, July 9th. UBS Group assumed coverage on Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective for the company. TD Cowen lowered their target price on Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a research report on Tuesday, September 22nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $370.68.

Stryker Trading Up 0.1%

NYSE SYK opened at $277.27 on Wednesday. The stock has a market capitalization of $106.35 billion, a price-to-earnings ratio of 28.73, a PEG ratio of 1.75 and a beta of 0.78. The stock’s 50 day moving average price is $304.41 and its two-hundred day moving average price is $314.34. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker has a 52 week low of $267.00 and a 52 week high of $392.55.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the business earned $3.13 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts anticipate that Stryker will post 14.96 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the transaction, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 351,267 shares of company stock worth $118,197,701 in the last ninety days. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SYK. State Street Corp grew its holdings in Stryker by 1.2% during the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock worth $4,903,772,000 after acquiring an additional 183,400 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Stryker by 0.6% during the second quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock valued at $2,571,357,000 after acquiring an additional 45,478 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Stryker during the second quarter valued at $1,404,284,000. Royal Bank of Canada lifted its holdings in shares of Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after purchasing an additional 199,863 shares during the period. Finally, Auto Owners Insurance Co lifted its holdings in shares of Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after purchasing an additional 2,906,448 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Barclays turned bullish on Stryker. Barclays initiated coverage with an “Overweight” rating and separately upgraded the stock to “Strong Buy,” signaling confidence in the company’s long-term medical-device growth prospects. Barclays initiates coverage of Stryker Corporation
• Positive Sentiment: The steep selloff has attracted value-oriented interest. Commentary suggests Stryker may be undervalued after its approximately 26% slide, with its established market position and long-term earnings potential offering support for a recovery thesis. Stryker stock could be cheap after its slide
• Neutral Sentiment: CEO succession is planned for January 1. Kevin Lobo will become executive chairman while Spencer Stiles becomes chief executive. The orderly transition could provide continuity, but investors may remain cautious while assessing Stiles’ strategy and execution. Stryker is changing CEOs
• Negative Sentiment: Near-term growth concerns remain the key overhang. Mar Vista Investment Partners said macroeconomic pressures and worries about Stryker’s near-term growth have overshadowed the company’s long-term quality and competitive strengths. Stryker near-term growth concerns
• Negative Sentiment: A law firm investigation adds headline risk. Pomerantz LLP is investigating potential claims on behalf of Stryker investors. The announcement does not establish wrongdoing, but it could increase uncertainty and weigh on sentiment following the stock’s substantial decline. Pomerantz investigation of Stryker

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.

Stryker’s product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.